Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases

Endocrinology and Metabolic Disorders

Creating Future of MedTech Industry with Artifi...

Artificial Intelligence is a breakthrough technology and has been used tremendously in this data-driven age, leading to a leap forward in the MedTech industry. Artificial Intelligence enrolls the u...

Dec 07, 2020

Osteosarcoma Market | Osteosarcoma key companies
Key Companies To Keep an Eye on for Pipeline Therapies in Osteosarcoma Market in the Next Decade

The current treatment approach for high-grade Osteosarcoma is conventional surgical resection of the primary tumor, along with systemic chemotherapies and radiation therapies in case of metastases and recurrence. Despite the rarity of Osteosarcoma, cancer poses a major global health burden with a global incidence r...

Find More
Osteosarcoma treatment market | Osteosarcoma unmet needs
Pitfalls of Current Osteosarcoma Treatment Approaches

Osteosarcomas are rare, yet are the leading cause of deaths due to cancer in the pediatric population. It is a high-grade malignancy of mesenchymal origins. They are the most frequent forms of primary bone tumors and account for approximately 20% of all the bone tumors. With the incident population of less than 250...

Find More
Acromegaly Pipeline | Acromegaly Companies |Therapies
What Does The Acromegaly Pipeline Have Up In Its Sleeve?

In the span of a decade, the Acromegaly pipeline therapies, including IONIS-GHR-LRx (Ionis Pharmaceuticals), ATL1103 (Antisense Therapeutics), CAM2029 (Camurus), Veldoreotide (Strongbridge Biopharma), CRN00808 (Crinetics Pharmaceuticals), and Lanreotide PRF (Ipsen) are set to launch. What happens when the grow...

Find More

More Views & Analysis

Leading-Causes-of-Death-Worldwide
What are the Top Five Leading Causes of Deaths in the World?

The global healthcare system over the past few decades has transformed exponentially. Today we are living twice as long as our ancestors have lived before. Infrastructure development, technological advancements (such as accurate diagnosis and lesser medical errors), public-private partnerships in healthcare, availa...

Find More

Metabolic Acidosis Market | MA Market
Metabolic Acidosis: Counting The Unmeasured Anions And Closing the Gap In Blood Serum

Metabolic Acidosis Market offers immense opportunities to the pharma players to explore, which currently is dominated by alkali therapies and lacks any approved therapy. Launch of Pipeline therapies and rising prevalence shall accelerate the MA market growth in 7MM+3EM by 2030. An acid-base disorder, Metabolic...

Find More

Alzheimer-Disease-Risk-Factors
The Question That Remains Unanswered: What Might Be Causing Alzheimer’s?

50 million people globally have dementia, and out of all the dementia cases, Alzheimer’s Disease accounts for about 60–70% of cases, says the WHO. Alzheimer's Disease is a neurodegenerative disease, a common cause of dementia that affects behavior, memory, and thinking abilities of an individual. Mostly the symptom...

Find More

pharma-news
Gene-edited T cells for diabetes treatment; Pliant raised $144 million; Accent, AstraZeneca aim RNA modifiers in cancer deal; NodThera Raises $55M;

Gene-edited T cells for diabetes treatment The Scientists at the Seattle Children's Research Institute and the Benaroya Research Institute have got a promising finding that will turn off the destructive autoimmune response in Type 1 diabetes. This comprises editing the genes of patients' T cells. The team pre...

Find More

Precision-Medicine
Precision Medicine: An emerging approach to conventional treatment

As per WHO, “Cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer”. The patients whose lives are afflicted with similar types of cancers have long been administered a similar type of treatment regimen b...

Find More

Recent-pharma-news
Algernon’s NP-120; FDA nod to 4DMedical tool; SaNOtize’s NORSTM trial; Pole’s capital increase

Algernon Pharmaceuticals has announced the submission of an Investigational New Drug (IND) application of its drug, NP-120 for COVID-19.  The company has submitted the IND with the US FDA for its planned multinational Phase 2b/3 study of its repurposed drug NP-120 (Ifenprodil) for the treatment of patients ...

Find More

Real-world evidence (RWE) is used in an exponential way to guide payment decisions and access system.....

Find More

Fragile X Syndrome is a syndrome, which results in intellectual disabilities as well as affects the .....

Find More

According to WHO, Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death g.....

Find More

The most common lysosomal disease, Gaucher Disease is a result of lack of sufficient glucocerebrosid.....

Find More

Delivery of therapeutics to the human eye is among the most interesting endeavours a formulator can .....

Find More

Doctors and scientists have recognized that traditional, complementary and alternative therapies hav.....

Find More